A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

NCT07219589 ↗

Phase 1 Recruiting 90 enrolled Hanmi Pharmaceutical Company Limited

RandomizedSequentialTriple-blindTreatment

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.

Timeline

Start: 2025-11-06
Primary completion: 2027-03
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HM17321	Unknown	—	Subcutaneous

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Summary

Timeline

Drugs

Indications